169 related articles for article (PubMed ID: 35529783)
1. The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases.
Zhou J; Wu Y; Xie M; Fang Y; Zhao J; Lee SY; Im Y; Ye L; Su C
Transl Lung Cancer Res; 2022 Apr; 11(4):656-669. PubMed ID: 35529783
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases.
Zhou J; Zhou F; Chu X; Zhao J; Wu Y; Zhao W; Xu C; Su C
Transl Lung Cancer Res; 2020 Apr; 9(2):316-324. PubMed ID: 32420071
[TBL] [Abstract][Full Text] [Related]
4. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681
[TBL] [Abstract][Full Text] [Related]
5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
6. Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.
Wang C; Mu S; Yang X; Li L; Tao H; Zhang F; Li R; Hu Y; Wang L
Front Oncol; 2023; 13():1110949. PubMed ID: 37213269
[TBL] [Abstract][Full Text] [Related]
7. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract][Full Text] [Related]
10. Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.
Xie X; Zhou M; Wang L; Wang F; Deng H; Yang Y; Sun N; Li R; Chen Y; Lin X; Liu M; Zhou C
Hum Vaccin Immunother; 2023 Aug; 19(2):2241310. PubMed ID: 37526078
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With
Huang Z; Yan H; Zeng L; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Dong X; Yang N; Zhang Y
JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
[TBL] [Abstract][Full Text] [Related]
13. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
[TBL] [Abstract][Full Text] [Related]
16. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
17. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
18. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
19. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]